(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Recurrent Hematologic Malignancy
City of Hope Medical CenterSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Recurrent Hematologic Malignancy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Antengene Therapeutics Limited | Phase 1/2 | B |
HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3 City of Hope Medical Center | Phase 2 | CCC |
Ipilimumab OHSU Knight Cancer Institute | Phase 1 | CC |
IBUPROFEN City of Hope Medical Center | Phase 1 | CC |
HYDROMORPHON City of Hope Medical Center | Phase 1 | CC |
RANITIDINE City of Hope Medical Center | Phase 1 | CC |
Irradiated Allogeneic Cells Rutgers, The State University of New Jersey | Early Phase 1 | C |
Same molecule, other indications
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →